821 related articles for article (PubMed ID: 8816385)
1. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
[TBL] [Abstract][Full Text] [Related]
2. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
3. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
4. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment.
Gammie JS; Li S; Colson YL; Demetris AJ; Neipp M; Ildstad ST; Pham SM
Exp Hematol; 1998 Sep; 26(10):927-35. PubMed ID: 9728927
[TBL] [Abstract][Full Text] [Related]
5. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
6. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
Taniguchi H; Abe M; Shirai T; Fukao K; Nakauchi H
J Immunol; 1995 Dec; 155(12):5631-6. PubMed ID: 7499847
[TBL] [Abstract][Full Text] [Related]
8. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.
Li H; Kaufman CL; Boggs SS; Johnson PC; Patrene KD; Ildstad ST
J Immunol; 1996 Jan; 156(1):380-8. PubMed ID: 8598488
[TBL] [Abstract][Full Text] [Related]
9. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
Soderling CC; Song CW; Blazar BR; Vallera DA
J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
[TBL] [Abstract][Full Text] [Related]
10. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts.
Li H; Inverardi L; Molano RD; Pileggi A; Ricordi C
Transplantation; 2003 Apr; 75(7):966-70. PubMed ID: 12698081
[TBL] [Abstract][Full Text] [Related]
11. Alloresistance to K locus class I-mismatched bone marrow engraftment is mediated entirely by CD4+ and CD8+ T cells.
Hayashi H; LeGuern C; Sachs DH; Sykes M
Bone Marrow Transplant; 1996 Aug; 18(2):285-92. PubMed ID: 8864436
[TBL] [Abstract][Full Text] [Related]
12. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
13. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
Li S; Salgar SK; Kurimoto Y; Yousem S; Pham SM
J Surg Res; 2008 May; 146(2):289-97. PubMed ID: 18314139
[TBL] [Abstract][Full Text] [Related]
14. CD8 T cell of donor splenocyte mixed with bone marrow cells is more effective than CD4 T cell for induction of donor-specific tolerance in sublethally irradiated mice.
Yoshida A; Narumi S; Hashimoto N; Itabashi Y; Hakamada K; Sasaki M
Transplant Proc; 2004 Oct; 36(8):2418-22. PubMed ID: 15561266
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
[TBL] [Abstract][Full Text] [Related]
17. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
Lee EN; Lee J; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Kwon CH; Joh JW; Kim SJ
J Surg Res; 2006 Jan; 130(1):102-9. PubMed ID: 16183077
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow transplantation combined with mesenchymal stem cells induces immune tolerance without cytotoxic conditioning.
Wang Y; Liu J; Xu C; Zhang W; Bai L; Li N; Liu Y; Wang Y; Su Y; Hu D
J Surg Res; 2011 Nov; 171(1):e123-31. PubMed ID: 21920556
[TBL] [Abstract][Full Text] [Related]
19. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism.
Xu H; Chilton PM; Huang Y; Schanie CL; Ildstad ST
J Immunol; 2004 Feb; 172(3):1463-71. PubMed ID: 14734723
[TBL] [Abstract][Full Text] [Related]
20. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
